<DOC>
	<DOC>NCT01570660</DOC>
	<brief_summary>Thiazoledinediones decrease blood glucose by their insulin-sensitizing properties. Here the investigators examined whether pioglitazone (PIO) improves insulin sensitivity independently of glycemic control and whether adipokines or non-esterfied fatty acids (NEFA) serve as mediators.</brief_summary>
	<brief_title>Phielix et al.: Hepatic Fat Content and Adipokines</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Pioglitazone</mesh_term>
	<criteria>well controlled patients with type 2 diabetes (Hb1Ac &lt; 8%) no insulin therapy no comorbidities stable medication use for the last 6 months stable body weight the last 6 months no diet in the last 6 months Hb1Ac &gt; 8% insulin therapy diabetesrelated comorbidities, like cardiovascular disease, neuropathology unstable medication use unstable body weight in the last 6 months (&gt; 5 kg) following a diet in the last 6 months</criteria>
	<gender>All</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2012</verification_date>
</DOC>